Triple-Combination Anti-LAG-3 and PD-1 Therapy for Solid Tumors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments for advanced solid tumors have limited effectiveness in improving overall survival, as they fail to adequately harness the immune system's potential against malignant tumors.
Innovation Solution
A pharmaceutical composition comprising a combination of an anti-LAG-3 antibody, a PD-1 pathway inhibitor, and an immunotherapeutic agent is administered to treat malignant tumors, aiming to enhance anti-tumor immune responses by targeting immune checkpoint pathways.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current cancer treatments are used for advanced solid tumors, then treatment is simpler and less costly, but effectiveness in improving overall survival is limited
Solution Approach 1:
The patent combines three distinct therapeutic agents into a single pharmaceutical composition: an anti-LAG-3 antibody, a PD-1 pathway inhibitor, and an immunotherapeutic agent. This triple-combination approach integrates multiple mechanisms of action (checkpoint inhibition and immune stimulation) into one treatment regimen, thereby improving overall survival effectiveness while managing complexity through formulation integration.
2Reliability
If a combination of anti-LAG-3 antibody, PD-1 pathway inhibitor, and immunotherapeutic agent is used, then anti-tumor immune response is enhanced, but treatment complexity increases
Solution Approach 1:
The patent merges three separate therapeutic agents into a single pharmaceutical composition that can be administered together. This combination includes an anti-LAG-3 antibody (blocking inhibitory signaling), a PD-1 pathway inhibitor (blocking another inhibitory pathway), and an immunotherapeutic agent (providing positive immune stimulation). The merging of these agents into one composition enhances anti-tumor immune response while presenting a unified treatment approach.
Solution Approach 2:
The pharmaceutical composition functions as a composite therapeutic material, combining multiple biologic agents with different mechanisms of action into a single formulation. This composite approach allows synergistic effects where the checkpoint inhibitors remove brakes on the immune system while the immunotherapeutic agent provides acceleration, creating a multi-component therapeutic system that addresses multiple aspects of tumor immune evasion simultaneously.
3Reliability
If multiple immune checkpoint pathways are targeted simultaneously, then immune system potential against cancer is more fully harnessed, but treatment cost and complexity increase
Solution Approach 1:
The patent combines three therapeutic agents into one pharmaceutical composition, thereby harnessing multiple immune checkpoint pathways (LAG-3 and PD-1) and additional immune stimulation mechanisms simultaneously. This merging approach fully exploits the immune system's anti-tumor potential by blocking multiple inhibitory pathways and providing positive immune activation in a single treatment, rather than requiring separate administrations of each agent.
Data Source
AI summary
Provided are methods for clinical treatment of malignant tumors (e.g., advanced solid tumors) using a combination of an anti-LAG-3 antibody, an anti-PD-1 antibody, and an immunotherapeutic agent.